-
1دورية أكاديمية
المؤلفون: Callahan, Margaret, Amin, Asim, Kaye, Frederic J, Morse, Michael A, Taylor, Matthew H, Peltola, Katriina J, Sharma, Padmanee, O'Reilly, Eileen M, Meadows Shropshire, Stephanie, O'Brien, Shaun, Tschaika, Marina, Le, Dung T
المساهمون: Bristol Myers Squibb
المصدر: Journal for ImmunoTherapy of Cancer ; volume 12, issue 2, page e007883 ; ISSN 2051-1426
مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy
-
2دورية أكاديمية
المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor
المساهمون: HUS Comprehensive Cancer Center, Department of Oncology
مصطلحات موضوعية: Budigalimab, Head and neck squamous cell cancer, Non-small cell lung cancer, PD-1 inhibitor, 3122 Cancers
وصف الملف: application/pdf
العلاقة: AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. Antoine Italiano: Consulting/advisory role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Lilly; honoraria: Bayer, Daiichi Sankyo, Lilly, Epizyme, Novartis, Roche; research funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono. Philippe A. Cassier: Honoraria: Novartis, Roche/Genentech, Blueprint Medicines, Amgen; research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme; Consultancy/advisory role: Merck Serono, Roche/Genentech. Chia-Chi Lin: Consulting/advisory role: Novartis, Boehringer Ingelheim, Blueprint Medicines; travel/accommodations/expenses: Lilly, Daiichi Sankyo, BeiGene, Novartis; honoraria: Novartis, Roche, Daiichi Sankyo. Tuomo Alanko: Consulting/advisory role: Bayer, Baxalta/Shire, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Kaiku Health; research funding: AbbVie, Bayer, Boehringer Ingelheim, BMS, Debiopharm, Eli Lilly, Incyte, MSD, Pfizer, Roche; travel/accommodations/expenses: Baxalta/Shire, BMS, MSD, Pfizer, Roche. Katriina J. Peltola: Consulting/advisory role: Orion Pharma, BMS, MSD, Novartis, Pfizer, Ipsen, Roche, Varian; stockholder: Faron Pharmaceuticals; speakers’ bureau: BMS, Pfizer, MSD; expert testimony: Ipsen; travel/accommodations/expenses: Roche, BMS; research funding: AbbVie, Bayer, BMS, MSD, Roche, Exelixis, Orion Pharma, Eisai, Novartis. Anas Gazzah: Travel, accommodations, congress registration expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; consultant/expert role: Novartis; principal/sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer HealthCare Ag, BBB Technologies BV, BeiGene, BioAlliance Pharma, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Exelixis, Forma, GamaMabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Servier IRIS, Janssen, Kura Oncology, Kyowa Kirin Pharmaceutical Development, Lilly, Loxo Oncology, Lytix Biopharma AS, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, OncoEthix, OncoMed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec GmbH, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; research grants: AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; nonfinancial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuix, Pfizer, Roche. Her-Shyong Shiah: The author declares no potential conflicts of interest. Emiliano Calvo: Consulting/advisory role: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier, amcure; speakers’ bureau: Novartis; research funding: AstraZeneca, BeiGene, Novartis, START; travel/accommodations/expenses reimbursement: Roche/Genentech; honoraria: HM Hospitales Group; stock/ownership interests: START, Oncoart Associated, International Cancer Consultants; president and founder of Foundation INTHEOS . Andrés Cervantes: Institutional research funding: AbbVie, Genentech, Merck Serono, BMS, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, FibroGen; advisory board or speaker fees: Merck Serono, Roche, Bayer, Servier, Pierre Fabre. Desamparados Roda: The author declares no potential conflicts of interest. Diego Tosi: Consulting/advisory role: BioMarin (immediate family member); research funding: Novartis, Astellas, Janssen; patent pending on a new drug combination for prostate cancer treatment; travel/accommodations/expenses: Janssen, Pfizer, Astellas Pharma; immediate family member had travel/accommodations/expenses from Nutricia and Amicus. Bo Gao: Consulting/advisory role: MSD. Michael Millward: Consulting/advisory role: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Takeda, Novartis; conference travel/support: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche. Lydia Warburton: Travel/accommodations/expenses: MSD, Merck. Minna Tanner: Consulting/advisory role: Roche, Novartis, Pfizer; speakers’ bureau: Roche, Novartis, Pfizer, Amgen. Gregory Vosganian: Former employee of AbbVie and may own stock. Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar: AbbVie employees and may own stock. Victor Moreno: Consulting fees: Merck, BMS, Janssen, Pieris; travel/accommodations: Regeneron/Sanofi; presentations: Nanobiotix; educational grant: Medscape/Bayer.; Italiano , A , Cassier , P A , Lin , C-C , Alanko , T , Peltola , K J , Gazzah , A , Shiah , H-S , Calvo , E , Cervantes , A , Roda , D , Tosi , D , Gao , B , Millward , M , Warburton , L , Tanner , M , Englert , S , Lambert , S , Parikh , A , Afar , D E , Vosganian , G & Moreno , V 2022 , ' First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma ' , Cancer Immunology, Immunotherapy , vol. 71 , no. 2 , pp. 417-431 . https://doi.org/10.1007/s00262-021-02973-wTest; 85109344549; 82232dae-2a73-44eb-98d3-0e87d81835e0; http://hdl.handle.net/10138/354706Test
-
3دورية أكاديمية
المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor
المساهمون: Tampere University, Department of Oncology
مصطلحات موضوعية: 3122 Cancers
وصف الملف: fulltext
العلاقة: Cancer Immunology, Immunotherapy; https://trepo.tuni.fi/handle/10024/133491Test; URN:NBN:fi:tuni-202107296405
الإتاحة: https://doi.org/10.1007/s00262-021-02973-wTest
https://trepo.tuni.fi/handle/10024/133491Test -
4دورية أكاديمية
المؤلفون: Bono, Petri, Massard, Christophe, Peltola, Katriina J., Azaro, Analia, Italiano, Antoine, Kristeleit, Rebecca S., Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V. J., Rodon, Jordi A.
المساهمون: HUS Comprehensive Cancer Center, Heikki Joensuu / Principal Investigator, Department of Oncology, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Clinicum, Helsinki University Hospital Area
مصطلحات موضوعية: ODM-203, dose escalation study, phase I, solid tumours, FGFR and VEGFR inhibitor, ENDOTHELIAL GROWTH-FACTOR, PROGNOSTIC-SIGNIFICANCE, INHIBITOR, VEGF, 3122 Cancers
وصف الملف: application/pdf
العلاقة: The study was sponsored by Orion Corporation, Orion Pharma, Espoo, Finland.; Bono , P , Massard , C , Peltola , K J , Azaro , A , Italiano , A , Kristeleit , R S , Curigliano , G , Lassen , U , Arkenau , H-T , Hakulinen , P , Garratt , C , Ikonen , T , Mustonen , M V J & Rodon , J A 2020 , ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ' , ESMO open , vol. 5 , no. 6 , 001081 . https://doi.org/10.1136/esmoopen-2020-001081Test; 98f21a47-b49b-43b7-b3d1-eb1e856f5e79; http://hdl.handle.net/10138/324382Test; 000597167800002
-
5دورية أكاديمية
المؤلفون: Peltola, Katriina J., Bono, Petri, Hugh Jones, Robert, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen , Mika V. J., Fizazi, Karim, Massard, Christophe
المساهمون: HUS Comprehensive Cancer Center, Department of Oncology, Heikki Joensuu / Principal Investigator, University Management
مصطلحات موضوعية: 3122 Cancers, 3126 Surgery, anesthesiology, intensive care, radiology, Androgen receptor, Castration-resistant prostate cancer, CYP17A1, ODM-204, Phase I clinical trial, ABIRATERONE, GENE, AMPLIFICATION, PROGRESSION
وصف الملف: application/pdf
العلاقة: Peltola , K J , Bono , P , Hugh Jones , R , Vjaters , E , Nykänen , P , Vuorela , A , Oksala , R , Pohjanjousi , P , Mustonen , M V J , Fizazi , K & Massard , C 2020 , ' ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer ' , European Urology Focus , vol. 6 , no. 1 , pp. 63-70 . https://doi.org/10.1016Test/j.euf.2018.08.022; RIS: urn:36741E580280AD791C9A6EE00A6CC7F0; 12b88df6-99aa-491c-b7d9-059e4a0fac3f; http://hdl.handle.net/10138/310589Test; 000505780500016
-
6دورية أكاديمية
المؤلفون: Bono, Petri, Massard, Christophe, Peltola, Katriina J., Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S., Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V.J., Rodon, Jordi A.
المصدر: Bono , P , Massard , C , Peltola , K J , Azaro , A , Italiano , A , Kristeleit , R S , Curigliano , G , Lassen , U , Arkenau , H T , Hakulinen , P , Garratt , C , Ikonen , T , Mustonen , M V J & Rodon , J A 2020 , ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ' , ESMO Open , vol. 5 , no. 6 , e001081 . ....
مصطلحات موضوعية: dose escalation study, FGFR and VEGFR inhibitor, ODM-203, phase I, solid tumours
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1136/esmoopen-2020-001081Test
https://curis.ku.dk/portal/da/publications/phase-iiia-openlabel-multicentre-study-to-evaluate-the-optimal-dosing-and-safety-of-odm203-in-patients-with-advanced-or-metastatic-solid-tumoursTest(7c12f293-11e9-4a2e-94ee-aba1d7c6b448).html
https://curis.ku.dk/ws/files/258769390/PIIS2059702920327654.pdfTest -
7دورية أكاديمية
المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory
المصدر: Cancer Immunology, Immunotherapy; Feb2022, Vol. 71 Issue 2, p417-431, 15p
مصطلحات موضوعية: NON-small-cell lung carcinoma, PEMBROLIZUMAB, HEAD & neck cancer, SQUAMOUS cell carcinoma, INTERFERON gamma
-
8دورية أكاديمية
المؤلفون: Peltola Katriina J, Sandholm Jouko, Aho Teija LT, Ito Yoshiaki, Koskinen Päivi J
المصدر: BMC Cell Biology, Vol 7, Iss 1, p 21 (2006)
العلاقة: http://www.biomedcentral.com/1471-2121/7/21Test; https://doaj.org/toc/1471-2121Test; https://doaj.org/article/20f3d3a397454eae879ac30bdf1d1a63Test
الإتاحة: https://doi.org/10.1186/1471-2121-7-21Test
https://doaj.org/article/20f3d3a397454eae879ac30bdf1d1a63Test -
9دورية أكاديمية
-
10دورية أكاديمية
المصدر: Laboratory Investigation ; volume 83, issue 9, page 1301-1309 ; ISSN 0023-6837
مصطلحات موضوعية: Cell Biology, Molecular Biology, Pathology and Forensic Medicine
الإتاحة: https://doi.org/10.1097/01.lab.0000087585.03162.a3Test
https://api.elsevier.com/content/article/PII:S0023683722034821?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0023683722034821?httpAccept=text/plainTest